Paradoxically, an emerging role for CD96 as a negative immune checkpoint was recently proposed, since antibodies targeting CD96 seemed to enhance the anti-tumor potential of CD8+ T-cells in a number of mouse tumor models (29). The gene discussed is CD8A; the disease is neoplasm.